Gast ::
| Hauptseite > Publikationsdatenbank > Progressive Multifocal Leukoencephalopathy > print |
| 001 | 1018540 | ||
| 005 | 20240311125737.0 | ||
| 024 | 7 | _ | |a 10.1212/WNL.0000000000207622 |2 doi |
| 024 | 7 | _ | |a 0028-3878 |2 ISSN |
| 024 | 7 | _ | |a 1526-632X |2 ISSN |
| 024 | 7 | _ | |a 10.34734/FZJ-2023-04868 |2 datacite_doi |
| 024 | 7 | _ | |a 37487750 |2 pmid |
| 024 | 7 | _ | |a WOS:001158672700001 |2 WOS |
| 037 | _ | _ | |a FZJ-2023-04868 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schweitzer, Finja |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Progressive Multifocal Leukoencephalopathy |
| 260 | _ | _ | |a [Erscheinungsort nicht ermittelbar] |c 2023 |b Ovid |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705497823_25936 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a JC polyomavirus (JCV) establishes an asymptomatic latent and/or persistent infection in most of the adult population. However, in immunocompromised individuals, JCV can cause a symptomatic infection of the brain, foremost progressive multifocal leukoencephalopathy (PML). In the past 2 decades, there has been increasing concern among patients and the medical community because PML was observed as an adverse event in individuals treated with modern (selective) immune suppressive treatments for various immune-mediated diseases, especially multiple sclerosis. It became evident that this devastating complication also needs to be considered beyond the patient populations historically at risk, including those with hematologic malignancies or HIV-infected individuals. We review the clinical presentation of PML, its variants, pathogenesis, and current diagnostic approaches. We further discuss the need to validate JCV-directed interventions and highlight current management strategies based on early diagnosis and restoring JCV-specific cellular immunity, which is crucial for viral clearance and survival. Finally, we discuss the importance of biomarkers for diagnosis and response to therapy, instrumental in defining sensitive study end points for successful clinical trials of curative or preventive therapeutics. Advances in understanding PML pathophysiology, host and viral genetics, and diagnostics in conjunction with novel immunotherapeutic approaches indicate that the time is right to design and perform definitive trials to develop preventive options and curative therapy for JCV-associated diseases. |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Laurent, Sarah |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Cortese, Irene |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Fink, Gereon Rudolf |0 P:(DE-Juel1)131720 |b 3 |
| 700 | 1 | _ | |a Silling, Steffi |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Skripuletz, Thomas |0 0000-0001-8550-335X |b 5 |
| 700 | 1 | _ | |a Metz, Imke |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Wattjes, Mike P. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Warnke, Clemens |0 0000-0002-3510-9255 |b 8 |e Corresponding author |
| 773 | _ | _ | |a 10.1212/WNL.0000000000207622 |g Vol. 101, no. 16, p. 700 - 713 |0 PERI:(DE-600)1491874-2 |n 16 |p 700 - 713 |t Neurology |v 101 |y 2023 |x 0028-3878 |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |u https://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.pdf |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |u https://juser.fz-juelich.de/record/1018540/files/post-print.pdf |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon |u https://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.gif?subformat=icon |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon-1440 |u https://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon-180 |u https://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.jpg?subformat=icon-180 |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon-640 |u https://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.jpg?subformat=icon-640 |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon |u https://juser.fz-juelich.de/record/1018540/files/post-print.gif?subformat=icon |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon-1440 |u https://juser.fz-juelich.de/record/1018540/files/post-print.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon-180 |u https://juser.fz-juelich.de/record/1018540/files/post-print.jpg?subformat=icon-180 |
| 856 | 4 | _ | |y Published on 2023-10-17. Available in OpenAccess from 2024-10-17. |x icon-640 |u https://juser.fz-juelich.de/record/1018540/files/post-print.jpg?subformat=icon-640 |
| 909 | C | O | |o oai:juser.fz-juelich.de:1018540 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131720 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROLOGY : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEUROLOGY : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|